MRI/TRUS data fusion for brachytherapy

TL;DR

This paper evaluates the impact of MRI/TRUS data fusion on prostate brachytherapy dose planning, showing that fusion improves prostate volume estimation and dose accuracy, potentially enhancing treatment reliability.

Contribution

It presents a preliminary evaluation of MRI/TRUS data fusion's effect on dosimetry in prostate brachytherapy, highlighting its potential to improve treatment planning.

Findings

TRUS prostate volume is often underestimated

Dose is overestimated in correlated manner

Dose constraints are maintained despite volume estimation issues

Abstract

BACKGROUND: Prostate brachytherapy consists in placing radioactive seeds for tumour destruction under transrectal ultrasound imaging (TRUS) control. It requires prostate delineation from the images for dose planning. Because ultrasound imaging is patient- and operator-dependent, we have proposed to fuse MRI data to TRUS data to make image processing more reliable. The technical accuracy of this approach has already been evaluated. METHODS: We present work in progress concerning the evaluation of the approach from the dosimetry viewpoint. The objective is to determine what impact this system may have on the treatment of the patient. Dose planning is performed from initial TRUS prostate contours and evaluated on contours modified by data fusion. RESULTS: For the eight patients included, we demonstrate that TRUS prostate volume is most often underestimated and that dose is overestimated in a correlated way. However, dose constraints are still verified for those eight patients. CONCLUSIONS: This confirms our initial hypothesis.